Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline

Canadian Journal of Surgery

Volumn 45, Issue 6, 2002, Pages 438-446

  Earle, Craig C ^a   Maroun, Jean ^a   Zuraw, Lisa ^a   Agboola, Olusegun ^a   Citron, Murray ^a   Cummings, Bernard ^a   Denardi, Franco G ^a   Figueredo, Alvaro ^a   Fine, Sheldon ^a   Fisher, Barbara ^a   Germond, Colin ^a   Jonker, Derek ^a   Khoo, Kong ^a   Kocha, Walter ^a   Lethbridge, Marion ^a   Lofters, Wycliffe ^a   Malthaner, Richard ^a   McLeod, Robin ^a   Moore, Malcolm ^a   Tandan, Ved ^a   Wong, Rebecca ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; DOSE RESPONSE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; LYMPH NODE METASTASIS; NEUROTOXICITY; PRACTICE GUIDELINE; STOMACH CARCINOMA; SURGICAL TECHNIQUE;

EID: 0036969371     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Physician Data Query. Gastric cancer. CancerNet. Available: www.cancer.gov/cancer_information/cancer_type/stomach (accessed April 1996).
2. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994;20:217-40.
3. Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer [review]. Ann Oncol 1995;6 Suppl 1:S17-26.
4. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995-9.
5. Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;113:502-12.
6. Dent DM, Werner ID, Novis B, Cheverton P, Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979;44:385-91.
7. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-54.
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes, NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
9. Longmire WP, Kuzma JW, Dixon WJ. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg 1968;167:293-312.
10. Serlin O, Wolkoff HS, Amadeo HM, Keehn RJ. Use of 5-fluorodeoxuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969;24:223-8.
11. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977;2:213-21.
12. Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978;16:209-16.
13. Nakajima T, Fukami A, Ohashi I, Kajitani T. Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5 fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 1980;10:187-94.
14. Huguier M, Destroyes H, Baschet C, Le Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection: a controlled study. Am J Surg 1980;139:197-9.
15. Schlag P, Schreml W, Gaus W, Herfarth C, Linder MM, Queisser W, et al. Adjuvant 5 fluorouracil and BCNU chemotherapy in gastric cancer: 3 year results. Recent Results Cancer Res 1982;80:277-83.
16. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982;49:1116-22.
17. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5FU and methyl CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group Report. Cancer 1983;52:1105-12.
18. Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother 1983;14:167-71.
19. Matsubara Y, Uragari Y, Yamamoto M, Goto M, Nakazato H, Imanaga H. A randomized clinical trial of adjuvant chemotherapy after resection in patients with stomach cancer. Clin Ther 1984;6:689-92.
20. Nakajima T, Takahashi T, Takagi K. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984;2:1366-71.
21. Engstrom PF, Lavin PT, Douglas HO, Brunner KW. Postoperative adjuvant 5 fluorouracil plus methyl CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275). Cancer 1985;55:1868-73.
22. Yamamura Y, Nishimura M, Sakamoto J, Yasui K, Morimoto T, Kato T, et al. [A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer.] Gan To Kagaku Ryoho 1986;13:2134-40.
23. The Italian Gastrointestinal Turnout Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988;75:1100-4.
24. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1989;1:571-4.
25. Coombes RC, Schein PS, Chilvers CE, Wils G, Beretta JM, Bliss A, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990;8:1362-9.
26. Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991;67:2454-8.
27. Hallissey MT, Dunn HA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectabie gastric cancer: five-year follow-up. Lancet 1994;343:1309-12.
28. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J. Positive results of adjuvant mitomycin C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993;29A:340-2.
29. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995;13:2757-63.
30. Chou FF, Sheen-Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol 1994;57:239-42.
31. MacDonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 1995;2:488-94.
32. Carrato A, Diaz-Rubio E, Medrano J, Calpena R, Marcuello E, Sanz J, et al. Phase III trial of surgery versus adjuvant chemotherapy with mitomycin and tegafur plus uracil (UFT), starting within the first week after surgery, for gastric adenocarcinoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:198 (abstract 468).
33. Neri B, de Leonardis B, Romano S, Andreoli F, Pernice LM, Bruno L, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996;73:549-52.
34. Tsavaris N, Tentas K, Kosmidis P, Mylonakis N, Sakelaropoulos N, Kosmas CH, et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996;42:220-6.
35. Nakajima T, Nashimoto A, Kitamura M, Kito Y, Iwanaga T, Okabayashi K, et al, for the Gastric Cancer Surgical Study Group. Adjuvant mitocycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999;354:273-7.
36. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-5.
37. Ducreux M, Nordlinger B, Ychou M, Milan C, Bouche O, Ducerf C, et al. Resected gastric adenocarcinoma: randomized trial of adjuvant chemotherapy with 5 FU-cisplatin (FUP). Final results of the FFCD 8801 trial [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000;19:241a (abstract 932).
38. Di Bartolomeo M, Bajetta E, Bordogna G, Aitini E, Fava S, Schieppati G, et al. Improved adjuvant therapy outcome in resected gastric cancer patients according to node involvement. 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) group [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000;19:241a (abstract 934).
39. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
40. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-64.
41. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-43.
42. Schiessel R, Funovics J, Schick B, Bohmig HJ, Depisch D, Hotbauer F, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma. Results of a randomized trial. Acta Med Austriaca 1989;16:68-9.
43. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguichi T, Yamane T, et al. Prophylaxis with carbon absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629-31.
44. Sautner T, Hotbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970-4.
45. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048-52.
46. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J CIin Oncol 1998;16:2733-8.
47. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugerbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347-54.
48. Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999;46:2035-8.
49. Kramling HJ, Wilkowski R, Duhmke E, Cramer C, Willich N, Schildberg RW. Adjuvant intraoperative radiotherapy of stomach carcinoma. Langenbecks Arch Chir Suppl Kongressbd 1996;113:211-3.
50. Jakesz R, Dittrich C, Funovics J, Hofbauer F, Rainer H, Reiner G, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988;110:44-51.
51. Kim J-P. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992;216:269-78.
52. Popiela T, Zembala M, Oszacki J, Jedrychowski W. A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 1982;13:182-4.
53. Imaizumi M, Kondo T, Kamei H, Ichihashi H. [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group)]. Gan To Kagaku Ryoho 1990;17:2397-403.
54. Kim J-P. Recent advances in gastric cancer therapy with immunochemosurgery. Asian J Surg 1997;20:115-8.
55. Langman MJ, Dunn JA, Witing JL, Burton A, Hallissey MT, Fielding JW, et al. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. Br J Cancer 1999;81:1356-62.
56. Skoropad V, Berdov B. Preoperative short-term radiotherapy of resectable gastric cancer: complete 20-years follow up of a randomized trial [abstract]. Eur J Cancer 1999;35 Suppl 4:S147 (abstract 542).
57. Skoropad V, Berdov B. Randomized trial of preoperative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer [abstract]. Eur J Cancer 1999;35 Suppl 4:S139 (abstract 508).
58. Gouchi A, Orita K, Fuchimoto S, Konaga E, Satoh K, Mannami T, et al. Randomized control study of preoperative intratumoral injection of OK-432 in gastric cancer patient. Ten years survival [abstract]. Proc Annu Meet Am Soc Clin Oncol 1997;16:263a (abstract 931).
59. Peters KM, Beuth J, Ko HL, Pulverer G, Kluger J, Grundmann R. Preoperative immunostimulation with Propionibacterium avidum KP-40 in patients with gastric carcinoma: a prospective randomized study. Onkologie 1990;13:124-7.
60. Terashima M, Takagane A, Sasaki T, Kusaka S, Kanno Y, Yashima T, et al. A prospective randomized trial of preoperative immunotherapy using PSK for the treatment of gastric cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998;17:304a (abstract 1170).
61. Songun I, Keizer HJ, Hermans J, Klementschitsch P, De Vries JE, Wils JA, et al, for The Dutch Gastric Cancer Group (DGCG). Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. Eur J Cancer 1999;35:558-62.
62. Fujii M, Kosaki G, Tsuchiya S, Kimura K, Suzuki H, Nakajima T, et al, for the Gastric Cancer Chemotherapy Group of Japan. Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1999;18:272a (abstract 1045).
63. Kang YK, Choi DW, Im YH, Kim CM, Lee JI, Moon NM, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1996;15:215 (abstract 503).
64. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-34.
65. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1981;8:1-11.
66. Alcobendas F, Mula A, Estape J, Curto J, Pera C. Mitomycin-C as an adjuvant in resected gastric cancer. Ann Surg 1983;198:13-7.
67. Hermans J, Bonenkamp H. Meta-analyses need time, collaboration, and funding [letter, reply]. J Clin Oncol 1994;12:879-80.
68. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
69. Sakamoto J, Nakazato H. [Evaluation of adjuvant immunochemotherapy in advanced gastric cancer.] Gan To Kagaku Ryoho 1993;20:2525-30.
70. Niimoto M, Hattori T, Ito I, Tamada R, Inokuchi K, Orita K, et al. Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I. Cancer Immunol Immunother 1984;18:13-8.
71. Ochiai T, Sato H. [Evaluation of postoperative immunotherapy of gastric cancer.] Gan To Kagaku Ryoho 1983;10:373-9.
72. Ochiai T, Sato H, Sato H, Hayashi R, Asano T, Isono K, et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 1983;43:3001-7.
73. Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, et al. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer - a randomized controlled trial. Jpn J Surg 1984;14:286-92.